Type2 Diabetes Clinical Trial
— DiabPuebloOfficial title:
Diabetes Pueblo Program - The Application and Acceptability of Culturally Appropriate Education Programs for Current or Potential Insulin Therapy Users With Type 2 Diabetes in the Latino Community
Verified date | September 2021 |
Source | Sansum Diabetes Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers, such as socioeconomic and cultural factors, to starting and optimizing therapies, including insulin. Latinos have cultural beliefs and behaviors specific to this population that should be appropriately addressed in a diabetes self-management education and support program. Diabetes Pueblo is a diabetes education program that may be a solution to help address the barriers Latinos with T2D have to diabetes care and insulin use. The Diabetes Pueblo program consists of two targeted diabetes education curriculums for the local Latino community: (a) Diabetes Fundamentals and (b) Insulin Success, a culturally appropriate program course addressing barriers to initiating and optimizing insulin and T2D therapies. We will explore if Diabetes Pueblo Program improves knowledge of lifestyle advice for healthy eating and physical activity, increase the propensity to use insulin when clinically indicated, and improve success rates with insulin therapy by addressing common fears and negative perceptions of T2D therapies in this population.
Status | Completed |
Enrollment | 25 |
Est. completion date | February 25, 2020 |
Est. primary completion date | February 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Individuals > 18 years of age 2. Self-reported Latino heritage 3. Fluent in Spanish 4. Type 2 diabetes diagnosis 5. Available to attend the educational series and all study visits 6. Willingness to have height, weight, waist circumference, and HbA1c measured before and after the educational course 7. Individuals with poor glycemic control, as defined by the following: - HbA1c = 8% at or prior to enrollment assessment (most recent lab within 3 months or provided at Sansum Diabetes Research Institute (SDRI) screening visit), OR - HbA1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months): - Fasting plasma glucose = 130 mg/dL - 2-hour post-prandial or random blood glucose = 180 mg/dL - =1 hypoglycemic event (blood glucose < 70 mg/dL) OR - Individuals new to insulin or being considered for insulin therapy by their healthcare provider 8. Willing and able to provide consent to take part in the study 9. Based on the research staff's judgment, participant must have a good understanding, ability, and willingness to adhere to the protocol Exclusion Criteria: 1. Has a cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the education program language that, in the opinion of the screener, would interfere with the ability to provide consent and participate/complete the program 2. Participation in other studies involving medications or device within 3 months prior to Visit 1 3. Known or suspected abuse of alcohol, narcotics, or illicit drugs 4. Current use of insulin pump 5. For females: Pregnancy or positive pregnancy test 6. Pharmaceutical employees or those employed in a position where they have a direct role in treating participants with diabetes. |
Country | Name | City | State |
---|---|---|---|
United States | Sansum Diabetes Research Institute | Santa Barbara | California |
Lead Sponsor | Collaborator |
---|---|
Sansum Diabetes Research Institute | Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Fingerstick for evaluation of HbA1c related to diabetes | HbA1c % will measured in a capillary fingerstick blood sample | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class | |
Other | Height measured by Physical exam | Height measured in centimeters or inches by physical exam | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class | |
Other | Weight measured by Physical exam | Weight measured in kilograms or pounds by physical exam | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class | |
Other | Waist circumference measured by Physical exam | Waist circumference measured in centimeters or inches by physical exam | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class | |
Other | Socio-demographics assessed by questionnaire | Socio-demographics measured by questionnaire - including age, gender, self-identified race/ethnicity, contact information, education, occupation, preferred language, insurance status, influenza & pneumonia immunization status, alcohol & tobacco use, birth place, physical activity, food security, and mobile phone use. | Visit 1, week 0 Screening | |
Other | Foot examination evaluated by Questions | Foot examination with 'yes or no' and frequency questions | Visit 1, week 0 Screening | |
Other | Neuropathy Questions | Questions about neuropathy | Visit 1, week 0 Screening | |
Other | Retinopathy Questions | Questions about retinopathy and eye exams | Visit 1, week 0 Screening | |
Other | Nephropathy Questions | Questions about nephropathy | Visit 1, week 0 Screening | |
Other | Medical history and medication status and history assessed by questionnaire | Medical history, including date of diabetes diagnosis, type of diabetes, diabetes education, diabetes self-care, depression and stress, falls, physician visits, hospital and emergency room visits, and current medications verified by visual inspection and medication history assessed by interview questionnaire | Visit 1, week 0 Screening | |
Other | Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire | Menopausal status, pregnancy status (number of live births, number of stillbirths, birthweights of live births, and any diagnosis of type 1 diabetes), and gestational diabetes history for female participants will be determined by questionnaire | Visit 1, week 0 Screening | |
Primary | Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes. | The Diabetes Pueblo program consists of two newly created, targeted education curriculums, Diabetes Fundamentals and Insulin Success, for Latino adults with type 2 diabetes. It will be delivered over the course of 11 weeks by designated promotores, community health workers, to approximately 20 study participants at Sansum Diabetes Research Institute. | 11 weeks | |
Secondary | Diabetes self management evaluated by questionnaire | The Diabetes Self-Management Questionnaire consists of 16 questions to evaluate diabetes self-care including glucose management, dietary control, physical activity, and health-care use. Questions are rated on a 4 point scale - 0 Does not apply to me, 1 Applies to me to some degree, 2 Applies to me to a considerable degree, 3 Applies to me very much. This yields an overall rating of self-care with higher scores indicating more effective diabetes self-care. | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class | |
Secondary | Insulin treatment evaluated by questionnaire | The Insulin Treatment Appraisal Scale is a validated 20-item questionnaire that will be used in insulin naïve and insulin-treated patients with type 2 diabetes to assess positive and negative perceptions regarding insulin treatment. Items are rated on a 5-point scale ("strongly disagree" to "strongly agree") and the mean of individual item scores is calculated to obtain a total score, with lower scores indicating less negative perceptions regarding insulin treatment. | Visit 1, week 0 Screening; Visit 2, week 8 End of Diabetes Fundamentals class; Visit 3, week 11 End of Insulin Success class | |
Secondary | Participant evaluation of Diabetes Pueblo evaluated by questionnaire | The first questionnaire includes curriculum content questions which are specific to courses 1-4, 5-8, and 9-10. | Class 4, week 4; Class 8, week 8; Class 10, week 10 | |
Secondary | Participant evaluation of Diabetes Pueblo evaluated by questionnaire | The second questionnaire assesses overall program feedback on the entire program. | Class 11, week 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|